New attack on deadly cancer: powerful drug combo before surgery
NCT ID NCT06155279
Summary
This study is testing whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy before surgery helps fight pleural mesothelioma more effectively. It involves 41 adults with early-stage, operable mesothelioma who haven't had prior cancer treatment. Patients receive three cycles of the drug combination, then undergo surgery, followed by more immunotherapy to try to control the disease and prevent it from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
-
Azienda Ospedaliera-Universitaria di Parma
Parma, Italy
-
Azienda Ospedaliero-Universitaria S. Anna
Ferrara, Italy
-
Centro di Riferimento Oncologico (CRO) IRCCS
Aviano, Pordenone, Italy
-
Humanitas Gavazzeni
Bergamo, Italia/Bergamo, 24125, Italy
-
IFO - Istituto Tumori Regina Elena, Roma
Roma, Italia/Roma, 00144, Italy
-
Istituto Clinico Humanitas
Rozzano, Milano, 20089, Italy
-
Istituto Oncologico Veneto IRCCS
Padua, 35128, Italy
Conditions
Explore the condition pages connected to this study.